Callitas Health Inc (CSE:LILY) (OTCMKTS:MPHMF) (FWB:T3F3), the clinical-stage pharmaceutical company, named former interim CEO Brian Keane capital markets and merger and acquisitions consultant.
READ: Callitas Health wins notice of allowance from US Patent and Trademark Office in regards to patent for new cannabis 'candy'
"We are proud to welcome Brian back to the Callitas team,” CEO James Thompson said. “As prior interim CEO, Brian is familiar with our patented delivery technology, as well as the multiple assets that are owned by the company that will be evaluated for monetization as we expand into the legal cannabis market.”
Callitas is a Cincinnati-based company focused on developing technologies to address weight management, female sexual health and wellness, and cannabis delivery.
Shares were unchanged on the CSE at C$10 and at $US0.09 on OTC markets.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel